MarketMoodz
Tenaya’s TN-401 Shows Early Arrhythmia Drops in PKP2 ARVC
Tenaya Therapeutics presented interim RIDGE-1 data at the ASGCT 2026 meeting showing its TN-401 gene therapy produced early reductions in arrhythmia burden in six adults with PKP2-associated ARVC. Biopsies detected TN-401 DNA and mRNA in cardiac tissue, and the therapy was generally well tolerated with no dose-limiting toxicities reported in nine months of follow-up.
Key Takeaways
- Six adults with PKP2-associated ARVC received a single TN-401 infusion at 3×10^13 or 6×10^13 vg/kg and all had reductions in premature ventricular contractions (PVCs).
- Mean PVC reductions were 60% in Cohort 1 and 67% in Cohort 2, based on the interim readout.
- Two patients with non-sustained VT (NSVT) saw steep declines: one from 78 events/24h to 0 by Week 52 and another from 43 to 4 events/24h by Week 20.
- Biopsy samples showed TN-401 transduction and expression (DNA and mRNA); PKP2 protein changes ranged from a 4% decrease to a 15% increase across samples.
- TN-401 was generally well tolerated with no dose-limiting toxicities; most treatment-related adverse events were temporary troponin or liver-enzyme elevations, and the dataset is interim and small, so results are preliminary.
People Involved
- No specific individuals mentioned
Entities Involved
- Tenaya Therapeutics (TNYA)Developer of TN-401 gene therapy and sponsor of the RIDGE-1 trial
- RIDGE-1 Phase 1b/2 trialTenaya’s clinical study evaluating TN-401 in PKP2-associated ARVC
- American Society of Gene & Cell Therapy (ASGCT)Venue where interim data were presented at the 2026 Annual Meeting
- Alnylam PharmaceuticalsContextual partner noted in background deals (up to $1.13B milestones)
MarketMoodz Analysis
For investors, the RIDGE-1 interim readout delivers a tidy early clinical signal: 60–67% mean PVC reductions across cohorts and marked NSVT declines in two patients suggest on-target electrophysiologic activity after a single infusion. Cardiac biopsy evidence of TN-401 DNA and mRNA strengthens the biological plausibility that the vector reached and expressed in myocardium, while the mixed PKP2 protein readouts (−4% to +15%) highlight variability that larger datasets must clarify. The safety profile—no dose-limiting toxicities and mainly transient troponin or liver-enzyme elevations—removes an immediate red flag, but nine months of follow-up in six patients is far from sufficient to judge durability or rare risks; investors should treat this as proof-of-concept rather than efficacy confirmation.
Historic context matters. Gene therapy for structural heart disease has lagged behind ocular and neurologic indications because delivery to myocardium, durable expression, and immune safety are tougher to achieve at scale. TN-401’s early transduction signal is encouraging relative to prior cardiac attempts that struggled with tissue delivery or tolerability, but small N and surrogate rhythm endpoints (PVCs/NSVT) limit clinical and regulatory extrapolation. Next inflection points to watch: expanded cohort data and randomized control arms, longer durability (beyond nine months), hard clinical endpoints such as ICD therapies/hospitalizations, manufacturing scale-up, and any updates on partnering or milestone triggers tied to larger collaborations. Confirmatory conference abstracts, peer-reviewed publication, and verified market data on TNYA will be critical for investment decisions.
Source: Original Article